Publication: Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury.
dc.contributor.author | Medina-Caliz, Inmaculada | |
dc.contributor.author | Robles-Diaz, Mercedes | |
dc.contributor.author | Garcia-Muñoz, Beatriz | |
dc.contributor.author | Stephens, Camilla | |
dc.contributor.author | Ortega-Alonso, Aida | |
dc.contributor.author | Garcia-Cortes, Miren | |
dc.contributor.author | González-Jimenez, Andres | |
dc.contributor.author | Sanabria-Cabrera, Judith A | |
dc.contributor.author | Moreno, Inmaculada | |
dc.contributor.author | Fernandez, M Carmen | |
dc.contributor.author | Romero-Gomez, Manuel | |
dc.contributor.author | Navarro, Jose M | |
dc.contributor.author | Barriocanal, Ana M | |
dc.contributor.author | Montane, Eva | |
dc.contributor.author | Hallal, Hacibe | |
dc.contributor.author | Blanco, Sonia | |
dc.contributor.author | Soriano, German | |
dc.contributor.author | Roman, Eva M | |
dc.contributor.author | Gomez-Dominguez, Elena | |
dc.contributor.author | Castiella, Agustin | |
dc.contributor.author | Zapata, Eva M | |
dc.contributor.author | Jimenez-Perez, Miguel | |
dc.contributor.author | Moreno, Jose M | |
dc.contributor.author | Aldea-Perona, Ana | |
dc.contributor.author | Hernandez-Guerra, Manuel | |
dc.contributor.author | Prieto, Martin | |
dc.contributor.author | Zoubek, Miguel E | |
dc.contributor.author | Kaplowitz, Neil | |
dc.contributor.author | Lucena, M Isabel | |
dc.contributor.author | Andrade, Raul J | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | European Regional Development Fund–FEDER | |
dc.contributor.funder | Agencia Española del Medicamento | |
dc.contributor.funder | CIBERehd | |
dc.contributor.group | Spanish DILI registry | |
dc.date.accessioned | 2023-01-25T08:32:35Z | |
dc.date.available | 2023-01-25T08:32:35Z | |
dc.date.issued | 2016-05-13 | |
dc.description.abstract | Chronic outcome following acute idiosyncratic drug-induced liver injury (DILI) is not yet defined. This prospective, long-term follow-up study aimed to analyze time to liver enzyme resolutions to establish the best definition and risk factors of DILI chronicity. 298 out of 850 patients in the Spanish DILI registry with no pre-existing disease affecting the liver and follow-up to resolution or ⩾1year were analyzed. Chronicity was defined as abnormal liver biochemistry, imaging test or histology one year after DILI recognition. Out of 298 patients enrolled 273 (92%) resolved ⩽1year from DILI recognition and 25 patients (8%) were chronic. Independent risk factors for chronicity were older age [OR: 1.06, p=0.011], dyslipidemia [OR: 4.26, p=0.04] and severe DILI [OR: 14.22, p=0.005]. Alanine aminotransferase (ALT), alkaline phosphatase (ALP) and total bilirubin (TB) median values were higher in the chronic group during follow-up. Values of ALP and TB >1.1 x upper limit of normal (xULN) and 2.8 xULN respectively, in the second month from DILI onset, were found to predict chronic DILI (p1.1 x upper limit of normal (xULN) and 2.8 xULN respectively, in the second month from DILI onset, were found to predict chronic DILI (p One year is the best cut-off point to define chronic DILI or prolonged recovery, with risk factors being older age, dyslipidemia and severity of the acute episode. Statins are distinctly related to chronicity. ALP and TB values in the second month could help predict chronicity or very prolonged recovery. Drug-induced liver injury (DILI) patients who do not resolve their liver damage during the first year should be considered chronic DILI patients. Risk factors for DILI chronicity are older age, dyslipidemia and severity of the acute episode. Chronic DILI is not a very common condition; normally featuring mild liver profile abnormalities and not being an important clinical problem, with the exception of a small number of cases of early onset cirrhosis. | |
dc.description.sponsorship | The present study has been supported by grants from the Instituto de Salud Carlos III co-funded by the European Regional Development Fund–FEDER (contract numbers: PI04/1688, PI12-00620, AC-0073-2013) and by the Agencia Española del Medicamento. CIBERehd is funded by the Instituto de Salud Carlos III. | |
dc.description.version | Si | |
dc.identifier.citation | Medina-Caliz I, Robles-Diaz M, Garcia-Muñoz B, Stephens C, Ortega-Alonso A, Garcia-Cortes M, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol. 2016 Sep;65(3):532-42 | |
dc.identifier.doi | 10.1016/j.jhep.2016.05.003 | |
dc.identifier.essn | 1600-0641 | |
dc.identifier.pmc | PMC7458366 | |
dc.identifier.pmid | 27184533 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458366/pdf | |
dc.identifier.unpaywallURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458366 | |
dc.identifier.uri | http://hdl.handle.net/10668/10089 | |
dc.issue.number | 3 | |
dc.journal.title | Journal of hepatology | |
dc.journal.titleabbreviation | J Hepatol | |
dc.language.iso | en | |
dc.organization | Hospital Torrecárdenas | |
dc.organization | Instituto de Investigación Biomédica de Málaga-IBIMA | |
dc.organization | Hospital Universitario Virgen de la Victoria | |
dc.organization | Hospital Costa del Sol | |
dc.organization | Hospital Universitario Regional de Málaga | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.page.number | 532-42 | |
dc.provenance | Realizada la curación de contenido 20/03/2025 | |
dc.publisher | Elsevier | |
dc.pubmedtype | Journal Article | |
dc.relation.projectID | PI04/1688 | |
dc.relation.projectID | PI12-00620 | |
dc.relation.projectID | AC-0073-2013 | |
dc.relation.publisherversion | https://linkinghub.elsevier.com/retrieve/pii/S0168-8278(16)30188-X | |
dc.rights.accessRights | Restricted Access | |
dc.subject | Chronic | |
dc.subject | Hepatotoxicity | |
dc.subject | Risk factors | |
dc.subject | Statins | |
dc.subject.decs | Dislipidemias | |
dc.subject.decs | Histología | |
dc.subject.decs | Alanina Transaminasa | |
dc.subject.decs | Fibrosis | |
dc.subject.decs | Inhibidores de Hidroximetilglutaril-CoA Reductasas | |
dc.subject.mesh | Alanine Transaminase | |
dc.subject.mesh | Chemical and Drug Induced Liver Injury | |
dc.subject.mesh | Follow-Up Studies | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Prospective Studies | |
dc.subject.mesh | Risk Factors | |
dc.title | Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. | |
dc.type | research article | |
dc.type.hasVersion | AM | |
dc.volume.number | 65 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- RISalud_Accesorestringido.pdf
- Size:
- 93.39 KB
- Format:
- Adobe Portable Document Format